Opinion
Video
ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL
Author(s):
A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.
EP: 1.Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators
EP: 2.Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies
EP: 3.Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies
EP: 4.CAR T-Cell Therapy’s Impact on Lymphoma Management
EP: 5.Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma
EP: 6.Challenges in CAR T-Cell Therapy for Lymphoma
EP: 7.Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents
EP: 8.CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma
EP: 9.Approaches to Treatment Sequencing in LBCL
EP: 10.Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics
Now Viewing
EP: 11.ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL
EP: 12.Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL
EP: 13.Observations in Progression Post-CAR T for Lymphoma
EP: 14.Emerging Bispecifics in the Treatment Paradigm for R/R LBCL
EP: 15.Future Perspectives in Large B-Cell Lymphoma
Related Videos
Related Content
%201%20(1)-Recovered%20copy.jpg?fit=crop&auto=format)
%201%20(1)-Recovered%20copy.jpg?fit=crop&auto=format)
